Case Study 08 – Biliary Tract Cancer
Patient: 68 years – Female diagnosed with Intrahepatic Cholangiocarcinoma Clinical Testing: Treatment Options: MEK Inhibitor (Binimetinib) treatment can be used
OneCell Diagnostics is now 1Cell.Ai
Patient: 68 years – Female diagnosed with Intrahepatic Cholangiocarcinoma Clinical Testing: Treatment Options: MEK Inhibitor (Binimetinib) treatment can be used
Patient: 69 years – Male diagnosed with Adenocarcinoma-Gallbladder Clinical Testing: Treatment Options: As per the NCCN recommendations ERBB2 mutations benefit
Patient: 54 years – Male diagnosed with Squamous cell carcinoma of Buccal Mucosa Clinical Testing: Treatment Options: Overall preclinical and
Patient: 52 years – Male diagnosed with Adenocarcinoma Lung with Brain metastasis Clinical Testing: Treatment Options: Osimertinib is standard of
Patient: 54 years – Female diagnosed with Recurrent Metastatic Ovarian Adenocarcinoma Clinical Testing: Treatment Options: Co-occurring mutations in BRAF and
Patient: 67 years – Male diagnosed with Well-Differentiated Adenocarcinoma of Stomach Clinical Testing: Treatment Options: Various pre-clinical and clinical trials
Patient: 48 years – Female diagnosed with left breast cancer Clinical Testing: Treatment Options: The presence of HER2 amplification suggests
Patient: 52 years – Female diagnosed with Signet Ring Cell Adenocarcinoma of Colon Clinical Testing: Treatment Options: The presence of
Shaping the Future of Precision Oncology From Barcelona, 1Cell.Ai joined global leaders at ESMO 2024 to showcase our latest innovations
Expanding Access to Precision Diagnostics in Asia 1Cell.Ai was proud to participate in Medlab Asia 2024, where we showcased our